At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating alemtuzumab, ofatumumab, and 1 other intervention for Stage I Chronic Lymphocytic Leukemia and 3 related conditions. Active but no longer recruiting, targeting 53 participants across 2 sites in 2 countries.
Detailed Summary
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving alemtuzumab together with ofatumumab may kill more cancer cells
Study Details
Timeline
Interventions
Given SC
Given IV
Correlative studies